BackgroundCheck.run
Search For

James R Paterniti, 76La Jolla, CA

Known as:
Jim Paterniti James R Drummond

James Paterniti Phones & Addresses

La Jolla, CA   

10833 Birch Bluff Ave, San Diego, CA 92131   

11715 Timberlake Dr, San Diego, CA 92131   

Brooklyn, NY   

Morristown, NJ   

Dover, NJ   

Get Report
Control this profile

Mentions for James R Paterniti

James Paterniti resumes & CV records

Resumes

James Paterniti Photo 10

President

Location:
San Diego, CA
Industry:
Pharmaceuticals
Work:
Paterniti Pharma R&D Consulting
President Huya Bioscience International
Therapeutic Area Expert Keck Graduate Institute
Advisor Amylin Pharmaceuticals 2004 - 2009
Senior Director, Research Program Planning and Project Management Amylin Pharmaceuticals 2001 - 2004
Senior Director, Pharmacology Ligand Pharmaceuticals 1998 - 2001
Director, Metabolic Disease Pharmacology
Education:
The City University of New York
Doctorates, Doctor of Philosophy, Biology
Skills:
Global R&D Expert, Cardiovascular Therapeutucs, Metabolic Diseases
James Paterniti Photo 11

James Paterniti

James Paterniti Photo 12

James Paterniti

Skills:
Cnc, Technician
James Paterniti Photo 13

James Paterniti

Publications & IP owners

Us Patents

Prevention And/Or Treatment Of Inflammatory Bowel Disease Using Pyy Or Agonists Thereof

US Patent:
2006012, Jun 8, 2006
Filed:
Jun 13, 2003
Appl. No.:
10/518128
Inventors:
Bronislava Gedulin - Del Mar CA, US
Andrew Young - Rancho Santa Fe CA, US
James Paterniti - San Diego CA, US
International Classification:
A61K 38/22
A61K 39/395
A61K 31/5377
US Classification:
514012000, 424145100, 514232500
Abstract:
A novel use of PYY or a PYY agonist is disclosed for treating a bowel condition such as inflammatory bowel disease (e.g. ulcerative colitis and Crohn's disease), bowel atrophy, loss of bowel mucosa and loss of bowel mucosal function. The novel use is based on the discovery and demonstration that administration of PYY or a PYY agonist to an animal can protect the colon from injury induced by a hapten known to induce colitis.

Purified Cardiogenin Isomer And Related Methods

US Patent:
2013034, Dec 26, 2013
Filed:
Dec 21, 2011
Appl. No.:
13/996446
Inventors:
Andreas Kyas - Aarau, CH
Ernst Freund - Erlinsbach, CH
Oliver Schlörke - Oberwil, CH
Joerg Lill - Aarau, CH
Lars Rogall - Aarau, CH
Dario Menia - Aarau, CH
Gary Elliott - Portland ME, US
James Paterniti - San Diego CA, US
Assignee:
HUYA BIOSCIENCE INTERNATIONAL LLC - San Diego CA
International Classification:
C07H 1/08
C07C 62/32
C07H 15/24
US Classification:
514 33, 536 181, 560116, 514557, 435377
Abstract:
A cardiogenin major isomer is obtained from a methanol extract of and separated from its minor isomer. The separation of the two isomers can be achieved by chiral phase chromatography, e.g., using a Chiralpak IC™ column. The purity of the isolated cardiogenin major isomer can be further increased by crystallization, yielding isolated cardiogenin major isomer having HPLC purity as high as 98.97% (a/a) at 210 nm and a potency of 95.50%) (w/w).

Peptide Yy And Peptide Yy Agonists For Treatment Of Metabolic Disorders

US Patent:
2002014, Oct 3, 2002
Filed:
Dec 14, 2001
Appl. No.:
10/016969
Inventors:
Richard Pittner - San Diego CA, US
Andrew Young - La Jolla CA, US
James Paterniti - San Diego CA, US
Assignee:
Amylin Parmaceuticals, Inc.
International Classification:
A61K038/43
US Classification:
424/094100
Abstract:
Methods and compositions are disclosed to treat metabolic disorders such as obesity, diabetes, and increased cardiovascular risk comprising administering a therapeutically effective amount of a PYY or a PYY agonist.

Purified Cardiogenin Isomer And Related Methods

US Patent:
2016020, Jul 21, 2016
Filed:
Aug 28, 2015
Appl. No.:
14/839810
Inventors:
- San Diego CA, US
Ernst FREUND - Erlinsbach, CH
Oliver SCHLÖRKE - Oberwil, CH
Joerg LILL - Aarau, CH
Lars ROGALL - Aarau, CH
Dario MENIA - Aarau, CH
Gary ELLIOTT - Portland OR, US
James PATERNITI - San Diego CA, US
International Classification:
C07C 62/32
C07H 15/24
Abstract:
A cardiogenin major isomer is obtained from a methanol extract of and separated from its minor isomer. The separation of the two isomers can be achieved by chiral phase chromatography, e.g., using a Chiralpak IC™ column. The purity of the isolated cardiogenin major isomer can be further increased by crystallization, yielding isolated cardiogenin major isomer having HPLC purity as high as 98.97% (a/a) at 210 nm and a potency of 95.50%) (w/w).

Peptide Yy And Peptide Yy Agonists For Treatment Of Metabolic Disorders

US Patent:
2014013, May 15, 2014
Filed:
Jan 24, 2014
Appl. No.:
14/163689
Inventors:
- Wilmington DE, US
- San Diego CA, US
James R. PATERNITI - San Diego CA, US
Assignee:
ASTRAZENECA PHARMACEUTICALS LP - Wilmington DE
AMYLIN PHARMACEUTICALS, LLC - San Diego CA
International Classification:
A61K 38/22
US Classification:
514 52, 514 97, 514 74
Abstract:
Methods and compositions are disclosed to treat metabolic disorders such as obesity, diabetes, and increased cardiovascular risk comprising administering a therapeutically effective amount of a PYY or a PYY agonist.

Possible Relatives

Joseph A Paterniti  Maurice J Paterniti  Michael D Paterniti  Robert J Paterniti  Tony Paterniti  James V Johnson  James C Stamps  James E Stanage  James I Stanaland  James E Stanard 

NOTICE: You may not use BackgroundCheck or the information it provides to make decisions about employment, credit, housing or any other purpose that would require Fair Credit Reporting Act (FCRA) compliance. BackgroundCheck is not a Consumer Reporting Agency (CRA) as defined by the FCRA and does not provide consumer reports.